Protective effect of Ficus capensis lyophilized extract against carboplatin-induced liver injury via inhibition of oxidative stress and inflammation in rats.

Patients who are receiving carboplatin therapy for cancer often experience toxic side effects. This study examined the effects of lyophilized aqueous leaf extracts of F. capensis (LALEFC) on oxidative stress and inflammatory markers in albino rats with carboplatin-damaged livers. We randomly assigned 35 rats to five experimental groups. Groups 2-5 underwent liver injury induction using carboplatin, while groups 1 and 2 served as the normal and carboplatin control groups, respectively. Groups 3-5 were the treatment groups. Treatments were performed for 17 days. We analyzed the quantitative phytochemical constituents of LALEFC using standard procedures and analyzed the liver oxidative stress and inflammatory markers using liver homogenate. The phytochemical constituents of LALEFC (mg/100 g) occur in the following order: The most abundant compounds were phenols (1577.72 ± 0.008), flavonoids (1253.13 ± 0.007), tannins (878.97 ± 0.007), alkaloids (652.66 ± 0.007), glycosides (314.39 ± 0.011), and terpenoids (261.18 ± 0.154), while steroids (0.573 ± 0.062), saponins (0.370 ± 0.003), and HCN (0.254.00 ± 0.006) were found in trace amount. The study of oxidative stress and inflammatory markers showed that giving carboplatin to rats greatly increased the levels of interleukin-1 (IL-1), interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), nuclear factor-kappa B (NF-α), malondialdehyde (MDA), reactive oxygen species (ROS), and caspase-3 activity. It also decreased the levels of reduced glutathione (GSH) and the activities of glutathione peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD). D). However, coadministration of LALEFC significantly restored the altered oxidative and inflammatory responses. This finding suggested that carboplatin induced liver injury through redox imbalance, which elevated the expression of inflammatory markers. LALEFC's restoration of altered markers could be relevant in the treatment of carboplatin-induced liver injury.

UCP-LF and other assay methods for schistosome circulating anodic antigen between 1978 and 2022.

Detection of circulating anodic antigen (CAA) is known for its high sensitivity in diagnosing schistosomiasis infection, even in low-prevalence settings. The Up-Converting Phosphor-Lateral Flow (UCP-LF) assay developed in 2008 presented greater sensitivity than other assay methods in use for CAA detection. Our study aims to comprehensively review all studies conducted in this area and thus generate informed conclusions on the potential for adopting the UCP-LF assay for diagnosing this important yet neglected tropical disease. Using the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines, we generated search criteria to capture all studies in English journals available in the Scopus and PubMed databases on 20 December 2022. A total of 219 articles were identified, and 84 that met the inclusion criteria were retrieved and eventually included in the study. Twelve different assay methods were identified with a noteworthy transition from enzyme-linked immunosorbent assay (ELISA) to the UCP-LF assay, a laboratory-based assay that may be applicable as a point-of-care (POC) diagnostic test for schistosomiasis. Reducing the time, cost, and dependence on specialized laboratory skills and equipment, especially relating to the trichloroacetic acid extraction step and centrifugation in the UCP-LF CAA assay may go a long way to aid its potential as a POC tool. We also propose the development of a CAA-specific aptamer (short protein/antigen-binding oligonucleotide) as a possible alternative to monoclonal antibodies in the assay. UCP-LF has great potential for POC application.